Written answers
Tuesday, 20 March 2018
Department of Health
Vaccination Programme
Michael Healy-Rae (Kerry, Independent)
Link to this: Individually | In context | Oireachtas source
451. To ask the Minister for Health his views on a matter (details supplied) regarding the Gardasil HPV vaccine; and if he will make a statement on the matter. [11929/18]
Michael Healy-Rae (Kerry, Independent)
Link to this: Individually | In context | Oireachtas source
476. To ask the Minister for Health his views on matters relating to the Gardasil HPV vaccine (details supplied); and if he will make a statement on the matter. [12091/18]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
I propose to take Questions Nos. 451 and 476 together.
The information that the Deputy seeks with regard to polysorbate 80 is not readily available. Therefore, I have asked the Health Products Regulatory Authority (HPRA) to investigate the matter and reply directly to the Deputy.
It is important to reiterate that the HPRA and the European Medicines Agency continually monitor adverse events to vaccination. HPV is one of the most closely studied and monitored medicinal products. The vast majority of reports received by the HPRA have been consistent with the expected pattern of short term adverse side effects for the vaccine, as described in the product information. Mild and temporary reactions to any kind of vaccination are not unusual.
No comments